Entity

Time filter

Source Type


Ozkan A.,Regional Research and Education Hospital | Kumtepe Y.,Ataturk University | Delibas I.B.,Nenehatun Obstetrics and Gynecology Hospital
Research Journal of Medical Sciences | Year: 2012

The objective of this study was to evaluate the 1 year success of the Mini Sling System in the treatment of Stress Urinary Incontinence (SUI). The subjects were 22 patients who had been treated with the Mini Sling system between July 2009 to January 2010 in the clinic. After diagnosis of genuine SUI by history, physical examination, cough stress pad test and urodynamics. The patients were evaluated at postoperative 1st, 3rd, 6th and 12th months, in terms of urinary incontinence, dyspareunia and lower urinary tract infection and symptoms. The mean operation time was 7 min. There were no intraoperative complications. At the 1st week of surgery, the Mini Sling System was totally removed from a patient due to confirmation of treatment failure. One patient had tissue reaction manifested by a palpable right inguinal nodularity at the postoperative 6th month and treated with partial mesh excision following antibiotherapy. The patient remained continent throughout the follow-up period. There were no other procedure-related complications detected within 1 year of follow-up. Objective cure and failure rates at 1 year follow-up were 95% (21/22) and 5% (1/22), respectively. In conclusion, the Mini Sling System is easy to use and effective minimally invasive method in the treatment of genuine stress incontinence. © Medwell Journals, 2012. Source


Tastekin D.,Istanbul University | Tambas M.,Istanbul University | Kilic K.,Kartal Educational and Research Hospital | Erturk K.,Istanbul University | Arslan D.,Regional Research and Education Hospital
Investigational New Drugs | Year: 2014

This open-labeled phase II, efficacy-finding study evaluated the efficiency and safety of Pistacia terebinthus soap in metastatic colorectal cancer patients who developed cetuximab induced skin toxicity. Patients who received cetuximab plus chemotherapy and developed Grade 2 or 3 skin toxicity were treated twice daily with a soap made of oil extracted from Pistacia terebinthus. During treatment, no topical or oral antibiotics, corticosteroids or other moisturizers were used. Patients were examined 1 week later and their photographs were taken. Fifteen mCRC patients who developed skin toxicity while receiving first-line CTX in combination with chemotherapy were included into the study. Eight patients were male and the median age was 58 (25-70). Sixty percent of the patients (n:9) had Grade 3 skin toxicity. Complete response rates in patients with Grade 2 and Grade 3 skin toxicities were 100 and 33 %, respectively. In the remaining patients with Grade 3 toxicity the skin toxicity regressed to Grade 1. The objective response rate was 100 %, and no delay, dose reduction or discontinuation of CTX treatment due to skin toxicity was necessary. Skin toxicity reoccurred in all patients when patients stopped administering the soap and therefore they used it throughout the cetuximab treatment. Pistacia terebinthus soap seemed to be used safely and effectively in the treatment of skin toxicity induced by Cetuximab. © 2014 Springer Science+Business Media New York. Source


Avsar U.,Ataturk University | Halici Z.,Ataturk University | Akpinar E.,Ataturk University | Yayla M.,Kafkas University | And 3 more authors.
Ostomy Wound Management | Year: 2016

Argan oil, produced from the kernels of the argan tree (Argania spinosa), has been shown to have antioxidant properties. To examine the effect of argan oil in second-degree burn wound healing, an in vivo experiment was conducted among 30 adult male Wistar rats divided into 5 equal groups: a sham group, a control group (burned but no topical agent), a group in which argan oil was applied once a day, a group in which argan oil was applied twice a day, and a group treated with 1% silver sulfadiazine once a day. Second-degree burns were created by scalding hot water (85° C for 15 seconds). Treatment began 24 hours after the burn injury; in the argan oil groups, 1 mL of argan oil was administered via syringe to the wound. The rate of wound healing was quantified by wound measurements on days 1, 7, and 14 after burn injury. Tissues were analyzed for molecular and histologic changes in TGF-β expression and fibroblast activity. Percent contraction of burned skin tissue was determined using the stereo investigator program, which calculated the burn field to the millimeter. Means (SD) were calculated and compared using Duncani¯s multiple comparison test. The group receiving argan oil twice daily showed significantly increased mRNA levels of TGF-β1 from 39.66-to 58.70-fold compared to the burn control group on day 14 (P <0.05). Both argan oil-treated groups showed significantly increased contraction compared to the burn control group at all 3 timepoints; the group receiving argan oil twice daily had a greater contraction rate (31% on day 7, 76% on day 14) than the silver sulfadiazine group (22% on day 7, 69% on day 14), (P <0.05). Histopathological assessments on days 3, 7, and 14 showed greater healing/contraction in both argan oil and silver sulfadiazine groups compared to the control group. These results suggest argan oil is effective in healing experimentally created second-degree burns in rats. Prospective, randomized, controlled clinical studies are needed to evaluate the safety, efficacy, and effectiveness of this treatment modality for patients with second-degree burn wounds. Source


Demir R.,Ataturk University | Cadirci E.,Ataturk University | Akpinar E.,Ataturk University | Cayir Y.,Ataturk University | And 6 more authors.
Basic and Clinical Pharmacology and Toxicology | Year: 2015

Diabetes mellitus (DM) is a major problem all over the world, affecting more people in recent years. Individuals with diabetes are more prone to disease than non-diabetics, especially vascular complications. The aim of this study was to examine the roles of the endothelin (ET)-1 in brain damage formed in a streptozocin (STZ)-induced diabetes model, and the effect of bosentan, which is the non-specific ET1 receptor blocker in the prevention of the diabetes-induced brain damage. To examine the effects of bosentan (50 mg/kg and 100 mg/kg) in this study, the rats were given the drug for 3 months. The rats were divided into four groups: the sham group (n = 10), the diabetic control group (n = 10), the group of diabetic rats given bosentan 50 mg/kg (n = 10) and the group of diabetic rats given bosentan 100 mg/kg (n = 10). Diabetes was induced in the rats by STZ (60 mg/kg i.p.). On day 91, all rats were killed. Brain tissues of the rats were measured by molecular, biochemical and histopathological methods. Antioxidant levels in the therapy groups were observed as quite near to the values in the healthy group. In this study, while the brain eNOS levels in the diabetic groups decreased, the ET1 and iNOS levels were found to be increased. However, in the diabetes group, hippocampus and cerebellum, pericellular oedema and a number of neuronal cytoretraction were increased in neuropiles, whereas these results were decreased in the therapy group. Based on all of these results, ET1 will not be ignored in diabetes-induced cerebral complications. © 2014 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society). Source


Keles S.,Ataturk University | Halici Z.,Ataturk University | Atmaca H.T.,Kirikkale University | Yayla M.,Ataturk University | And 6 more authors.
Investigative Ophthalmology and Visual Science | Year: 2014

Purpose. We compared the anti-inflammatory effects of bosentan and dexamethasone in endotoxin-induced uveitis (EIU). Methods. Endotoxin-induced uveitis was induced by subcutaneous injection of lipopolysaccharide (LPS, 200 μg) in Wistar rats. Rats were divided randomly into 10 groups (n = 6). Bosentan at doses of 50 and 100 mg/kg were administered orally 1 hour before and 12 hours after LPS injection, and dexamethasone was administered by intraperitoneally 30 minutes before and 30 minutes after LPS injection at a dose of 1 mg/kg. Data were collected at two time points for each control and treatment; animals were killed at either 3 or 24 hours after LPS injection. Histopathologic evaluation and aqueous humour measurements of TNF-α level were performed, and endothelin-1 (ET-1), inducible nitric oxide synthase (iNOS), and endothelin receptor A and B (EDNRA and B) expression were analyzed. Results. The group treated with 100 mg/kg bosentan at 24 hours displayed significantly milder uveitis and fewer inflammatory cells compared to LPS-injected animals, and there were similar findings in the dexamethasone-treated group at 24 hours. The TNF-α levels in the dexamethasone treatment group were lower than those in the LPS-induced uveitis control group (P < 0.05); however, there was no difference between the dexamethasone and bosentan treatment groups at 3 and 24 hours after LPS administration. Bosentan treatment at doses of 50 and 100 mg/kg significantly decreased iNOS expression compared to LPS-injected animals (P < 0.001). The ET-1 expression was suppressed significantly by bosentan and dexamethasone at 3 and 24 hours after LPS administration (P < 0.001). The EDNRA expression in the bosentan treatment groups was statistically significantly lower than that in the LPS-induced uveitis control group at 3 and 24 hours after LPS administration (P < 0.05). Conclusions. Bosentan reduces intraocular inflammation and has similar effects as dexamethasone in a rat model of EIU. © 2014 The Association for Research in Vision and Ophthalmology, Inc. Source

Discover hidden collaborations